Literature DB >> 1646127

An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast.

R S du Toit1, A P Locker, I O Ellis, C W Elston, R I Nicholson, J F Robertson, R W Blamey.   

Abstract

One-hundred-and-seventy-one patients with invasive lobular carcinomas have been matched with 342 patients with non-lobular invasive carcinomas for lymph node stage, tumour differentiation and patient age on a one to two basis. The two groups were investigated for differences in prognostic factors, survival, disease-free interval, metastatic patterns, receptor status, response to endocrine therapy after distant metastases and bilateral cancer rates. Patients with lobular carcinomas survived significantly longer than patients with carcinomas of no specific type, particularly in survival from the time of diagnosis of distant metastases; lobular carcinomas more often responded to endocrine treatment for systemic disease. Lobular cancers had a significantly higher rate of local recurrence, particularly after treatment by excision and breast irradiation. No differences were found between the two groups with respect to regional or distant recurrence rates, distant organ involvement patterns, distant metastatic free intervals and receptor status. Bilateral cancer was more frequent in patients with lobular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646127

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  14 in total

1.  Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base.

Authors:  S Eva Singletary; Lina Patel-Parekh; Kirby I Bland
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

2.  The relationship between hormone therapy use at the time of diagnosis of breast cancer and tumor characteristics.

Authors:  Mary Panjari; Robin Bell; Marijana Lijovic; Maria La China; Max Schwarz; Pamela Fradkin; Jo Bradbury; Helen Farrugia; Susan R Davis
Journal:  Horm Cancer       Date:  2010-03-09       Impact factor: 3.869

3.  Successful laparoscopic investigation and resection of solitary colonic metastasis from breast cancer (with video).

Authors:  Hisatsugu Maekawa; Takahisa Fujikawa; Akira Tanaka
Journal:  BMJ Case Rep       Date:  2012-11-14

4.  Factors that influence the incidence of breast cancer in Arica, Chile (Review).

Authors:  Gloria M Calaf; Fresia Caba; Jorge Farias; Francisco Rothhammer
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

5.  Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology.

Authors:  Claudia R Baquet; Shiraz I Mishra; Patricia Commiskey; Gary L Ellison; Mary DeShields
Journal:  J Natl Med Assoc       Date:  2008-05       Impact factor: 1.798

6.  Expression of metalloproteases and their inhibitors in different histological types of breast cancer.

Authors:  J M Del Casar; S González-Reyes; L O González; J M González; S Junquera; M Bongera; M F García; A Andicoechea; C Serra; F J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-15       Impact factor: 4.553

7.  Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma.

Authors:  Ja Seung Koo; Woohee Jung
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

8.  Spectral morphometric characterization of breast carcinoma cells.

Authors:  I Barshack; J Kopolovic; Z Malik; C Rothmann
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

9.  Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma.

Authors:  S Toikkanen; L Pylkkänen; H Joensuu
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 10.  Aspects of molecular phenotype and its correlations with breast cancer behaviour and taxonomy.

Authors:  A M Hanby
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.